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Abstract
Background: To assess comorbid DSM-IV-TR Axis I disorders in adolescent inpatients referred for treatment of
substance use disorders.
Methods: 151 patients (mean age 16.95 years, SD = 1.76; range 13 - 22) were consecutively assessed with the
Composite International Diagnostic Interview (CIDI) and standardized clinical questionnaires to assess mental
disorders, symptom distress, psychosocial variables and detailed aspects of drug use. A consecutively referred
subgroup of these 151 patients consisting of 65 underage patients (mean age 16.12, SD = 1.10; range 13 - 17) was
additionally assessed with the modules for attention-deficit/hyperactivity disorder (ADHD) and conduct disorder
(CD) using The Schedule for Affective Disorders and Schizophrenia for school-aged children (K-SADS-PL).
Results: 128 (84.8%) of the 151 patients were dependent on at least one substance, the remaining patients fulfilled
diagnostic criteria for abuse only. 40.5% of the participants fulfilled criteria for at least one comorbid present Axis I
disorder other than substance use disorders (67.7% in the subgroup additionally interviewed with the K-SADS-PL).
High prevalences of present mood disorder (19.2%), somatoform disorders (9.3%), and anxiety disorders (22.5%)
were found. The 37 female participants showed a significantly higher risk for lifetime comorbid disorders; the
gender difference was significantly pronounced for anxiety and somatoform disorders. Data from the underage
subgroup revealed a high prevalence for present CD (41.5%). 33% of the 106 patients (total group) who were
within the mandatory school age had not attended school for at least a two-month period prior to admission. In
addition, 51.4% had been temporarily expelled from school at least once.
Conclusions: The present data validates previous findings of high psychiatric comorbidity in adolescent patients
with substance use disorders. The high rates of school refusal and conduct disorder indicate the severity of
psychosocial impairment.
Background
T h em i s u s eo fp s y c h o t r o p i cs u b s t a n c e si so n eo ft h e
most prevalent mental disorders in industrial nations
and drug use is a frequent problem therapists in both
adolescent and adult psychiatric settings must deal with.
Johnston et al. [1] stated that 47% of all US-American
adolescents have tried an illicit drug by the time they
finish high school with cannabis being the predominant
illicit drug. Estimated lifetime prevalences of substance
use disorders (SUD) in adolescence range from 4.6% [2]
to 12.3% [3]. Treatment research on both clinically
ascertained adult substance-users [4] and on drug users
in the adult general population [5,6] emphasise the basic
negative influence of comorbid psychopathology on the
outcome of drug-specific treatment, abstinence and rate
of relapse. While a few community studies on adoles-
cent drug use and their link to comorbid disorders and
psychosocial problems have been conducted [6-11], only
single studies examined the concurrent occurrence of
SUD and other axis-I disorders on adolescent drug abu-
sers seeking specific drug treatment [12,13]. Whereas
epidemiological studies of the general population have
often assessed all common axis-I diagnoses, the majority
of studies concerning adolescent SUD and psychiatric
comorbidity focused on selected comorbid mental
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and depression: [18]; psychosis: [19,20]; various disor-
ders: [21-26] or presented data based on broad diagnos-
tic categories (“internalizing - externalizing” [27],
“affective disorders - anxiety disorders” [28]). To our
knowledge, only three recent studies on adolescent
SUD-inpatients presented comprehensive data on the
most common DSM axis-I disorders using standardized
clinical interviews [29-31]. Only Kelly et al. [31] assessed
comorbidity according to DSM-IV [32] whereas Jainchill
et al. [30] and Hovens et al. [29] used DSM-III-R criteria
[33].
Reflecting the health care system in many countries,
most studies were conducted on outpatients or patients
in residential programs. As a result, there is insufficient
knowledge about psychiatric comorbidity in adolescent
inpatients. As far as we know, only Deas et al. [28] and
Hovens et al. [29] conducted their studies on inpatients,
whereas other studies focused on outpatients or residen-
tial patients or considered inpatients within a heteroge-
neous group of inpatient, outpatient and residential
patients [22,31].
To evaluate the temporal stability and developmental
pathways of comorbid mental disorders, data on both
current and lifetime comorbidity are required. However,
to our knowledge, all recent studies limit the timeframe
to either current or lifetimed i s o r d e r s .F u r t h e r m o r e ,
even the rates of current disorders are not based on the
same timeframe; 12-month-, six-month and point preva-
lences of disorders are accepted indices to describe rates
of present morbidity.
In light of the aforementioned limitations it should be
noted that adolescent SUD patients very often suffer
from externalizing disorders (Oppositional defiant disor-
der, CD, ADHD) and to a somewhat lesser extent from
anxiety and mood disorders. Based on ten recent stu-
dies, Couwenbergh et al. [13] computed weighted means
for the most relevant disorders: Mood disorders (26%),
a n x i e t yd i s o r d e r s( 7 % ) ,P T S D( 1 1 % ) ,A D H D( 2 2 % ) ,C D
(64%), and any comorbid mental disorder (74%).
Little research has been conducted on the conse-
quences of maladaptive substance use concerning,
school refusal and the link to comorbid mental disor-
ders. Although some researchers [22,27,29] describe
aspects of school attendance, there is still a lack of
information about this important parameter of social
functioning.
Psychiatric SUD treatment of adolescent inpatients
differs in various ways from SUD treatment or detoxifi-
cation of adults. Many practitioners agree that inpatient
adolescent SUD treatment far more often has to account
for specific difficulties like inactivity, high rates of treat-
ment dropout and oppositional disorders. In many cases
it remains unclear whether these problems are part of
an age-appropriate developmental process or symptoms
of a mental disorder. In the case of a comorbid axis-I
disorder, misinterpreting these symptoms as normal
adolescent-like behaviour or part of the substance use
disorder would possibly delay the treatment of the
comorbid disorder for a considerable time.
Although some practice-oriented treatment programs
have been developed in the last decade many therapy
concepts focus on consumption-related symptoms of
SUD like withdrawal or maintenance of abstinence.
Relating to the detoxification of adults or outpatient
treatment of moderate SUD, this priority may be a rea-
sonable approach. In the area of inpatient SUD treat-
ment of adolescents this procedure runs the risk of
neglecting severe psychosocial symptoms like school
refusal or evolving delinquent/aggressive behaviour. This
present study aims to provide further comprehensive
data on psychiatric comorbidity of adolescents with sub-
stance use disorders with an additional focus on both
gender aspects and school refusal. Furthermore we
address some developmental psychopathological data as
we include both lifetime and present axis-I diagnoses
considering the changes in psychopathology.
Methods
Participants
Participants were 151 (114 male, 37 female) adolescents
and young adults (≤22 years) referred for inpatient sub-
stance abuse treatment between April 2005 and Decem-
ber 2006. Patients were consecutively recruited in
SUD-treatment units of the Rheinische Kliniken Essen
(99 patients) and Kreiskrankenhaus Gummersbach - Kli-
nik Marienheide (52 patients). Both units are located
within child and adolescent psychiatric departments,
providing full-service psychiatric health care. The Rhei-
nische Kliniken Essen is situated in a metropolitan area
of Germany whereas the Klinik Marienheide is located
in a rural region. The procedure of admission to both
drug-specific inpatient programs was comparable; in
both units patients were required to be heavy drug users
with clinically significant impairment or distress. Inclu-
sion criteria were at least one SUD (other than tobacco-
SUD) according to DSM-IV-TR [34], age between 12
a n d2 2y e a r sa n di n p a t i e n ttreatment for at least two
weeks. Patients were only excluded from the study if
they were suffering from a severe acute psychotic disor-
der or a comparable condition, thus unable to partici-
pate in a clinical interview (n = 2). Study participation
w a ss t r i c t l yv o l u n t a r ya n ds i g n e di n f o r m e dc o n s e n tw a s
obtained from all participants and (in the case of
minors) their parents/guardians. The participants and
their parents/guardians had been informed about the
study both orally and in written form. Only eight
patients refused to participate. None of the remaining
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of the participants was 16.95 years (SD = 1.76), ranging
from 13 to 22. The two study groups did not differ sig-
nificantly in age (t = .996, p = .321) or gender (phi =
.106, p = .233). Detailed site comparisons can be found
in table 1. In the two weeks prior to admission, 34.5% of
all participants lived together with their parents, 19.6%
with a single parent, 18.9% in youth welfare service
homes or residential programs for drug abusing adoles-
cents and 18.2% of the subjects lived on their own
(sometimes supported by social workers) or together
with their partner or friends; 4.1% lived together with
relatives or in a foster family, and 4.7% of the partici-
pants defined their life situation prior to admission as
“miscellaneous”, most often including short term home-
lessness. The study was approved by the Ethics commit-
tee of the University Duisburg-Essen.
Measures
During the second or third week of inpatient treatment,
independent face-to-face interviews and questionnaires
were conducted with the subjects. All interviews and
questionnaires were administered by trained medical stu-
dents or graduated, experienced clinical psychologists.
One experienced clinical psychologist for each hospital
acted as supervisor and guided the examiners. The clini-
cal examinations lasted three and a half hours on average
and were composed of six modules.
(1) The German edition [35,36] of the Composite Inter-
national Diagnostic Interview (CIDI) [37]. This compu-
terized interview measures DSM-IV Axis I disorders
including substance-related disorders, mood, psychotic,
anxiety, adjustment, somatoform and eating disorders.
(2) To access the DSM-IV-TR disorders ADHD and
conduct disorder (DSM-IV-TR code 312.8), which are
not included in the CIDI, the corresponding modules of
the Schedule for Affective Disorders and schizophrenia
for school-aged children - Present and Lifetime Version
- German version (K-SADS-PL, Version 1.0) [38-40]
were additionally administered consecutively to a limited
subgroup (n = 65) of underage (< 18 years) participants.
A present diagnosis represents a disorder that fulfils the
respective DSM-IV-TR criteria during the last six
months, lifetime diagnosis includes any diagnosis that
appeared during lifetime, including present disorders
(3) The Fagerström Test for Nicotine Dependence
(FTND) [41] was used to rate the extent of nicotine-
addiction on a dimensional scale.
Table 1 Site comparison
Site 1 (Essen)
n=9 9
Site 2 (Gummersbach)
n=5 2
Present (%) Lifetime (%) Present (%) Lifetime (%)
Gender
male 78 (78.8) - 36 (69.2) -
Age (Mean) 17.95 (SD = 1.84) - 16.75 (SD = 1.61) -
SUD
a
Alcohol 36 (36.4) 44 (44.4) 13 (25.0) 14 (26.9)*
Cannabis 80 (80.8) 86 (86.9) 38 (73.1) 42 (80.8)
Amphetamine-like substances 22 (22.2) 28 (28.3) 5 (9.6) 6 (11.5)*
Hallucinogens
b 7 (7.1) 11 (11.1) 0 (0.0) 1 (1.9)*
Cocaine 8 (8.1) 9 (9.1) 0 (0.0)* 1 (1.9)
Opiates 10 (10.1) 10 (10.1) 1 (1.9) 1 (1.9)
Inhalants 1 (1.0) 2 (2.0) 1 (1.9) 1 (1.9)
Sedative 2 (2.0) 4 (4.0) 0 (0.0) 2 (3.8)
Polysubstance 0 (0.0) 1 (1.0) 13 (25.0)*** 15 (28.8)***
Mood disorders 21 (21.2) 23 (23.2) 8 (15.4) 10 (19.2)
Anxiety disorders 17 (17.2) 21 (21.2) 17 (32.7)* 19 (36.5)*
Adjustment disorder 0 (0.0) 0 (0.0) 2 (3.8)* 2 (3.8)*
Somatoform disorders 8 (8.1) 14 (14.1) 6 (11.5) 8 (15.4)
ADHD
c 3 (12.0) 8 (32.0) 3 (7.5) 5 (12.5)
Conduct disorder
c 12 (48.0) 19 (76.0) 15 (37.5) 20 (50.0)*
Axis I disorder(s)
d 36 (36.4) 41 (41.4) 25 (48.1) 28 (53.8)
Note:
a SUD = Substance use disorder: abuse or dependence according to DSM-IV-TR, without nicotine SUD.
b including psychotropic mushrooms.
c Subgroup,
n = 65.
d without CD and ADHD. * p < .05, ** p < .01, *** p < .00.
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list-90-R (SCL-90-R) [43] evaluates a broad range of
psychological problems and symptoms of psychopathol-
ogy. Due to the high degree of reading difficulties appar-
ent in the patients, this questionnaire was additionally
orally explained by the investigators.
(5) Detailed information about drug-consumption for
all relevant substances (e.g. onset of drug-use, present
substance use, consumption in the last 30 days)
obtained by comprehensive semi-structured interviews
was recorded.
(6) A semi-structured interview slightly modified
according to the Adolescent Drug Abuse Diagnosis
(ADAD) [44] was used to collect data about school
attendance, life situation and state of health.
Due to the fact that some parents of the participants
either did not cooperate in a required manner or had
no contact to their children for a long time, all inter-
views and questionnaires were carried out with the
patients only.
Statistical Analyses
Means, standard deviations and percentages were calcu-
lated to describe aspects of drug-use. To study possible
differences between groups, the phi coefficient was used
to examine nominal data, Student’st - t e s tf o ri n t e r v a l
and ANOVA for comparisons of interval data with
more than two groups. Tests of significance were two-
tailed using exact tests procedure for nonparametric sta-
tistics. The level of statistical significance was set at p <
.05. Missing data (in five cases) have been substituted by
the mean of the respective variable. All statistical ana-
lyses were carried out using SPSS V14.0.
Results
Substance use
Tobacco (99.3%), cannabis (84.8%) and alcohol (64.9%)
were the most commonly used substances as well as the
substances most often associated with SUD (table 2).
Regarding present dependence on illicit drugs, nearly
half of the patients were dependent on cannabis only
(table 3). Patients who fulfil criteria for a present alcohol
or cannabis dependence used these substances for a sig-
nificantly longer time than patients without present
dependence (table 4). With regard to nicotine depen-
dence (measured with the FTND), the mean score of
5.18 (SD = 2.16) was in the range of a medium nicotine
dependence. 13.2% of the patients were rated as having
a very low level of nicotine dependence, 17.2% as having
low dependence, 20.5% medium, 39.1% high and 9.9% as
having a very high nicotine dependence.
Prevalence of comorbid mental disorders
Dysthymic disorders, posttraumatic stress disorder and
anxiety disorders in general were commonly found as
comorbid diagnoses (table 5). Moreover, the patients
who were additionally interviewed with the K-SADS
revealed high rates of present CD and even higher life-
time rates of CD seemingly indicating that a notable
proportion (30.8%) of lifetime CDs had remitted at time
of admission. An analysis of links between ADHD and
CD showed that 84% of the participants with a lifetime
diagnosis of ADHD also had a lifetime diagnosis of CD
(phi = .251, p = .059). Moreover, patients with one or
more lifetime comorbid mood disorders (entire sample)
tended to be older (17.52, SD = 1.92 vs. 16.81, SD =
1.70; T = -1.96, p = .052) than patients without a mood
Table 2 Substance use and substance use disorders
Consume* (%) Age of first use
(SD)
Days of use*
#
(SD)
Present disorder
+ (%) Lifetime disorder (%)
present lifetime abuse dependence SUD abuse dependence SUD
Tobacco 150
(99.3)
151
(100)
11.57 (2.21) 29.67 (2.32) - - - - - -
Alcohol 98 (64.9) 145
(96,0)
12.97 (1.73) 8.80 (7.74) 29
(19.2)
20 (13.2) 49 (32.5) 42
(27.8)
29 (19.2) 58 (38.4)
Cannabis 128
(84.8)
150
(99.3)
13.22 (1.46) 18.57 (9.10) 17
(11.3)
101 (66.9) 118
(78.1)
39
(25.8)
106 (70.2) 128
(84.8)
Ecstasy 33 (21.9) 88 (58.3) 15.24 (1.46) 5.87 (5.12) 8 (5.3) 19 (12.6) 27 (17.9) 15 (9.9) 22 (14.6) 34 (22.5)
Amphetamine 54 (35.8) 102
(67.5)
15.30 (1.44) 10.50 (9.05) 8 (5.3) 19 (12.6) 27 (17.9) 15 (9.9) 22 (14.6) 34 (22.5)
Hallucinogens
a 13 (8.6) 66 (43.7) 15.69 (1.31) 2.83 (2.82) 3 (2.0) 4 (2.6) 7 (4.6) 6 (4.0) 6 (4.0) 12 (7.9)
Cocaine 13 (8.6) 58 (38.4) 16.09 (1.72) 8.31 (7.42) 1 (.7) 7 (4.6) 8 (5.3) 2 (1.3) 8 (5.3) 10 (6.6)
Opiates 6 (4.0) 23 (15.2) 15.26 (1.84) 26.17 (6.15) 4 (2.6) 7 (4.6) 11 (7.3) 6 (4.0) 8 (5.3) 11 (7.3)
Inhalants 7 (4.6) 34 (22.5) 14.76 (2.13) 12.57 (10.33) 0 (0) 2 (1.3) 2 (1.3) 1 (.7) 2 (1.3) 3 (2.0)
Polysubstance - - - - 2 (1.3) 11 (7.3) 13 (8.6) 3 (2.0) 13 (8.6) 16 (10.6)
*consume in the last 30 days,
#calculated for those patients with present consumption,
+criteria fulfilled for the last six months,
aincluding psychotropic
mushrooms; all percentages are based on the total study group of n = 151.
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number of comorbid diagnoses (table 6) was detectable.
With one exception (present somatoform disorders), no
statistical relationship between age and specific comor-
bid axis-I disorders could be found (table 7).
Psychological variables
Results from the symptom-checklist SCL-90-R revealed
no statistically significantly elevated symptom distress in
our sample in comparison to norm values (table 8). Par-
ticipants with at least one present comorbid axis-I disor-
der (total group) showed significantly higher rates of
somatization (T = 55,44 vs. T = 49,01; t = -3.10, p <
.01) than participants without present comorbid Axis I
disorders. In addition, significant higher rates for obses-
sive-compulsive symptoms, anxiety, hostility, phobic
anxiety, paranoid ideation, psychoticism, global severity
index and positive symptom total score were found in
participants with one or more present comorbid mental
disorders (p < .05).
No relationship was found between substance-use
clusters (as listed in table 3) and symptom distress
scores.
School attendance
106 patients (mean age = 16.05, SD = 1.09) still required
mandatory schooling during the current school year
upon admission. Of this subgroup, 33.0% had not at all
attended school during the last two months prior to
admission. The mean number of absent days for actually
school attending participants (n = 71) during the last
two months (46 days of school attendance) was 17.72
days (SD = 18.40). 51.4% of the school aged participants
had been temporarily expelled from school at least once,
32.4% had to change schools as a disciplinary action. All
participants were asked to rate their performance at
school during the last year (or last year of school atten-
dance in case of no current school attendance) on a
three-point Likert scale ranging from below average (1)
over average (2) to above average (3). 51.3% rated their
school achievement below average, 45.3% average and
3.3% above average.
Gender differences
Female participants suffered significantly more often
f r o mo n eo rm o r el i f e t i m ea n do n eo rm o r ep r e s e n t
comorbid mental disorders (total group) (73.0% vs.
36.8%; phi = .312, p = .000 and 62.2% vs. 33.3%; phi =
.253, p = .002, respectively). In detail, female participants
significantly more often fulfilled criteria for lifetime and
present PTSD (18.9% vs. 4.4%; phi = .231, p < .010), pre-
sent (37.8% vs. 17.5%; phi = .209, p = .014) and lifetime
(40.5% vs. 21.9%; phi = .181, p = .033) anxiety disorders,
present (21.6% vs. 5.3%; phi = .243, p = .006) and lifetime
(32.4% vs. 8.8%; phi = .288, p = .001) somatoform disor-
ders than males. A female preponderance (diagnoses
include ADHD and CD) was also detectable in the under-
a g es u b g r o u pb u td i dn o tr e a c h statistical significance
(present diagnosis: 66.7% vs. 48.0% vs.; phi = .169, p =
.083; lifetime: 90.0% vs. 77.8%; phi = .145, p = .241). No
significant difference in the mean number of comorbid
diagnoses of patients with at least one comorbid disorder
(without ADHD & CD) between females and males was
found (present: 1.3 vs. 1.5, T = .85, p = .40; lifetime: 1.44
vs. 1.62, T = .76, p = .45). Additional t-tests showed no
significant differences in symptom distress measured
with SCL-90-R between male and female participants.
Data from the subgroup (additionally evaluated for
ADHD and CD) indicated no relationship between gen-
der and rates of CD or ADHD (present and lifetime).
Table 3 Present substance dependence (excluding
nicotine dependence)
Substance present dependence
(%)
Cannabis only 69 (45.7%)
Polysubstance use 11 (7.3%)
Cannabis and amphetamine-like substances 10 (6.6%)
Alcohol only 9 (6.0%)
Cannabis and alcohol 7 (4.6%)
other single substances, dependence rates
<=2 %
5 (3.3%)
other substance use combinations 17 (11.3%)
No present dependence 23 (15.2)
Table 4 Duration of substance use in years in relationship to both dependency and comorbidity
Substance use (years)
Dependence*
Mean (SD)
No dependence*
Mean (SD)
Nominal p Comorbidity
+
Mean (SD)
No comorbidity
+
Mean (SD)
Nominal p
Alcohol 5.05 (2.48) 3.85 (1.91) .018 4.19 (1.85) 3.90 (2.15) .387
Cannabis 4.11 (1.89) 2.96 (1.50) .001 3.91 (1.89) 3.61 (1.82) .329
Amphetamine 2.42 (1.90) 1.78 (1.38) .098 1.82 (1.49) 1.95 (1.52) .665
Ecstasy 2.73 (2.05) 1.89 (1.41) .063 1.94 (1.63) 2.09 (1.52) .654
Note: *referred to the corresponding substance, present diagnoses.
+Present axis-I disorders excluding ADHD and CD.
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Due to the different forms of treatment, the evaluation
of SUD prevalences in clinical samples is difficult.
Nevertheless our results are basically consistent with
other results [21,22,28]. In contrast to distributions of
SUD found in studies on adolescents in the German
general population [45], cannabis and amphetamine
SUD seem to be overrepresented in our sample whereas
alcohol related disorders were proportionally less often.
Regarding the severity of abuse or dependence (our can-
n a b i sp a t i e n t su s e dt h i sd r u go na v e r a g eo n6 2 %o ft h e
days of a month; Deas et al. [28] reported only half as
many drugs for their cannabis users) and social
deviances (data from the subgroup: 41.5% present
comorbid conduct disorder), our sample represents a
highly affected and deviant group of drug using
adolescents.
Our SUD-patients most frequently suffered from
comorbid mental disorders, predominantly conduct dis-
order and often anxiety and mood disorders. The high
general risk of present comorbidity (40.5%; patients with
additional K-SADS: 67.7%) found in this study is com-
parable to rates reported by most other studies (61% to
88%) of clinical SUD-samples [13]. In accordance to
previous studies [22,25,30,31], our results affirm the
high prevalence of comorbid disruptive behaviour symp-
toms in adolescent SUD-patients. High lifetime rates of
CD have also been found by other authors [17]. In con-
trast to a some studies [14,25,29] our sample demon-
strated comparatively moderate rates of ADHD which
were similar to those reported by Wise et al. [26], Han-
nesdóttir et al. [23] and also by Grilo et al. [15] who
found no difference in rates of ADHD between psychia-
tric inpatients with and without SUD.
In comparison with studies that assessed axis-I disor-
der rates in the German general population, our rates of
lifetime diagnoses seem to be only slightly higher than
rates found in representative cohorts: Essau et al. [3]
scanned 1035 adolescents (aged 12 to 17) of the general
population also using the German version of the CIDI
and found somewhat lower rates (according to DSM-IV)
for affective disorders (17.9% vs. 21.9%), anxiety disor-
ders (18.6% vs. 26.5%, especially PTSD: 1.6% vs. 7.9%)
and somatoform disorders (13.1% vs. 14.6%). With
regard to the general lifetime occurrence of one or
more axis-I disorders (including ADHD and CD), ado-
lescents studied by Essau et al. [3] showed a substan-
tially lower rate of psychiatric morbidity (Essau et al. s
data includes also SUD) (41.9% vs. 81.5%). This differ-
ence can partially be explained by the high rate of
Table 5 Comorbid DSM-IV-TR diagnoses
Total
(n = 151) Age = 16.95 (1.76)
Subgroup (with K-SADS)
(n = 65)
a Age = 16.12 (1.10)
Present (%) Lifetime (%) Present (%) Lifetime (%)
Mood disorder 29 (19.2) 33 (21.9) 12 (18.5) 13 (20.0)
Major depressive episode 5 (3.3) 7 (4.6) 3 (4.6) 4 (6.2)
Dysthymic disorder 24 (15.9) 24 (15.9) 8 (12.3) 8 (12.3)
Bipolar disorders 3 (2.0) 6 (4.0) 2 (3.1) 3 (4.6)
Anxiety disorder 34 (22.5) 40 (26.5) 19 (29.2) 22 (33.8)
Panic disorder with agoraphobia 4 (2.6) 5 (3.3) 2 (3.1) 3 (4.6)
Panic disorder w/o agoraphobia 3 (2.0) 3 (2.0) 0 (0.0) 0 (0.0)
Specific phobia 10 (6.6) 13 (8.6) 3 (4.6) 4 (6.2)
Social phobia 2 (1.3) 4 (2.6) 1 (1.5) 3 (4.6)
Obsessive-compulsive disorder 2 (1.3) 2 (1.3) 2 (3.1) 2 (3.1)
Posttraumatic stress disorder 12 (7.9) 12 (7.9) 9 (13.8) 9 (13.8)
Generalized anxiety disorder 3 (2.0) 4 (2.6) 1 (1.5) 1 (1.5)
Anxiety disorder NOS 3 (2.0) 3 (2.0) 3 (4.6) 3 (4.6)
Adjustment disorder 2 (1.3) 2 (1.3) 2 (3.1) 2 (3.1)
Somatoform disorders 14 (9.3) 22 (14.6) 8 (12.3) 13 (20.0)
Eating disorders 0 (0) 0 (0) 0 (0) 0 (0)
ADHD - - 6 (9.2) 13 (20.0)
Conduct disorder - - 27 (41.5) 39 (60.0)
Axis I disorder(s) 61 (40.5)* 69 (45.7)* 44 (67.7) 53 (81.5)
Note: ADHD = Attention-Deficit/Hyperactivity Disorder; CD = Conduct disorder; NOS = Not otherwise specified.
aonly participants 17 years old or younger. *without CD and ADHD.
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Page 6 of 9conduct disorder in our sample. Another large (n =
3021) representative epidemiological study [2] also
found lower rates of axis-I disorders in the general
population; these participants (aged 14 to 24) less often
fulfilled criteria for present axis-I disorders in general
(without SUD, ADHD and CD) (17.5% vs. 40.5%), mood
disorders (10.1% vs. 19.2%) especially dysthymic disorder
(2.9% vs. 15.9%), anxiety disorders (9.3% vs. 22.5%) and
somatoform disorders (0.7% vs. 9.3%) than participants
from our sample which affirms the assumption of higher
psychopathology in adolescents with SUD.
Except for the positive distress index in patients with
at least one comorbid diagnosis, data obtained via the
SCL-90-R demonstrated no clinically significant (T ≥
60) degree of psychological distress either in patients
with or without comorbidity. Considering the impair-
ments which are most often associated with mental dis-
orders, SUD and broken home situations, these results
are difficult to interpret. Dissimulation to avoid long-
term treatment, distorted self-perception and the reliev-
ing influence of inpatient treatment (“honeymoon
effect”) could possibly account for these results.
Comparable to Hovens et al. [29] (54% of the partici-
pants had dropped out of school) and Grella et al. [22]
(38% not attending school), our data suggest that ado-
lescent SUD is highly linked to school refusal and weak
performance: In the two months prior to admission only
67.6% of the participants attended school or a compar-
able institution at least occasionally, being on average
absent every other day. In possible relation to this beha-
viour, half of the participants judged their school perfor-
mance as below average.
Our finding that more girls suffer from comorbid dis-
orders than boys is consistent with the sparse literature
[28,30] however some investigators did not find this
relation [15]. Considering the different forms of treat-
ment and study settings, this apparent inconsistency
may reflect the effect of selective samples. The overre-
presentation of boys (75.5%) in our clinical sample of
SUD patients basically seems to reflect the proportion
of substance abusing boys and girls in the German gen-
eral population [2,45].
Limitations
First of all, our sample is highly selective due to local
modalities of admission. Transferences to other popula-
tion groups are therefore difficult. In the light of the
fact that substance use preferences and availability do
vary across Germany and Europe, our- two-centre-
design limits the generalisability of our results. However
we provided data on days of substance use per month
and school attendance to enable comparisons. Further-
more, our sites cover both an urban and a rural region,
limiting the restriction on one possible sub-culture. At
the present time, it is difficult to estimate the direction
and impact of this possible bias. Incorrectly too high as
well as too low rates of comorbidity are imaginable.
The sole implementation of the child version of the
K-SADS-PL was inevitable (regarding the familiar difficul-
ties the participants expressed) but led to a limited reliabil-
ity of the diagnoses of CDa n dA D H D .S y m p t o m so f
external disorders (e.g. CD and ADHD) are underreported
Table 6 Number of comorbid DSM-IV-TR diagnoses (without SUD)
Total
(n = 151) Age = 16.95 (1.76)
Subgroup (with K-SADS)
(n = 65)
a Age = 16.12 (1.10)
Present (%) Lifetime (%) Present (%) Lifetime (%)
Mean number of diagnoses (SD) .58 (SD .89) .71 (SD 1.00) 1.18 (SD 1.10) 1.65 (SD 1.22)
0 90 (59.6) 82 (54.3) 21 (32.3) 12 (18.5)
1 43 (28.5) 44 (29.1) 23 (35.4) 22 (33.8)
2 14 (9.3) 17 (11.3) 10 (15.4) 13 (20.0)
3 2 (1.3) 5 (3.3) 10 (15.4) 13 (20.0)
4 1 (.7) 2 (1.3) 1 (1.5) 5 (7.7)
5 0 (0) 0 (0) 0 (0) 0 (0)
6 1 (.7) 1 (.7) 0 (0) 0 (0)
Table 7 Correlation between age and comorbidity
Mean Age (SD) t p
Present
comorbidity
No present
comorbidity
Mood disorders 17.52 (1.92) 16.81 (1.70) -1.96 .052
Anxiety disorders 16.85 (1.46) 16.97 (1.85) .35 .725
Adjustment
disorder
16.50 (.71) 16.95 (1.77) .36 .719
Somatoform
disorders
16.29 (.73) 17.01 (1.82) 2.93 .006
ADHD
a 16.50 (.55) 16.08 (1.13) -.88 .381
Conduct
disorder
a
16.11 (1.01) 16.13 (1.17) .07 .942
Axis I disorder
(s)
b
17.00 (1.65) 16.91 (1.84) -.30 .762
Note:
aSubgroup, n = 65.
bwithout CD and ADHD.
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Page 7 of 9by adolescents in comparison to their parents [46]. It is
impossible to judge to which extent some of the diagnosed
disorders might not actually reflect a disorder directly
attributable to the consequences of SUD, thus rendering
the diagnosis of a substance induced disorder more
appropriate.
Conclusions
The high rate of comorbid psychopathology in inpatient
SUD-patients, particularly conduct disorder has implica-
tions for therapy and framework of specialized treat-
ment-units. Three-quarter of all patients show distinct
comorbid psychopathology and SUD therapists should
be able to take up this challenge. Patients with such a
high rate of conduct disorder require specialised forms
of treatment able to cope with high levels of aggression
and treatment abortion often associated with CD.
Future research should investigate the causal and tem-
poral relationship between conduct disorder and SUD,
especially in respect of early developmental trajectories.
Besides mental disorders, the high rate of school refusal
and truancy should also be considered as important part
of the substance use problem. Existing school refusal
treatment programmes should be aware of the high co-
occurrence whereas SUD-treatment units should care-
fully evaluate psychological causes of school refusal and
emphasize school reintegration. Finally, controlled longi-
tudinal comparative studies are needed to test the possi-
ble positive effect of comorbidity-considering treatment
programmes.
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